Fortrea Holdings Inc. (FTRE)
| Market Cap | 3.27B |
| Revenue (ttm) | 3.11B |
| Net Income (ttm) | -3.40M |
| Shares Out | 89.37M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | 34.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,004,840 |
| Open | 36.98 |
| Previous Close | 37.54 |
| Day's Range | 36.29 - 37.40 |
| 52-Week Range | 24.93 - 41.02 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 38.14 (+4.24%) |
| Earnings Date | May 7, 2024 |
About FTRE
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for FTRE stock is "Buy." The 12-month stock price forecast is $38.14, which is an increase of 4.24% from the latest price.
News
Fortrea Announces Date for First Quarter 2024 Financial Results and Conference Call
DURHAM, N.C., April 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its first quarter 2...
Fortrea sells enabling services and patient access businesses for up to $345 mln
Contract research firm Fortrea Holdings on Monday said it will sell two of its businesses to private equity firm Arsenal Capital Partners for up to $345 million.
Fortrea Signs Definitive Agreement to Divest Endpoint Clinical and Patient Access Businesses to Arsenal Capital Partners
Proposed divestiture of Endpoint Clinical and Fortrea Patient Access businesses further streamlines Fortrea's strategic focus as a pure-play contract research organization
Fortrea Reports Fourth Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance
For the three months and full year ended December 31, 2023: Revenues of $775.4 million for the fourth quarter, $3,109.0 million for the full year GAAP net loss of $(36.0) million for the fourth quarte...
Fortrea Increases Patient Access Capabilities and Cold Chain Expertise with FortreaRx™ Expansion
Fortrea's non-commercial specialty pharmacy expansion delivers flexible, scalable solutions to customers and life-changing medications direct to patients Fortrea's non-commercial specialty pharmacy ex...
Fortrea to Present at the Barclays 26th Annual Global Healthcare Conference
DURHAM, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Chairman and Chief Executive Officer, Tom Pike and C...
Fortrea Announces Date for Fourth Quarter and Full Year 2023 Financial Results and Conference Call
DURHAM, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its fourth quarter a...
Fortrea Establishes Industry Partnership with Veeva and Advarra to Streamline Patient and Site Clinical Trial Experience
Companies partner to provide patients and sites with easy access to study information in one integrated solution Companies partner to provide patients and sites with easy access to study information i...
Fortrea Previews J.P. Morgan Healthcare Conference Updates
DURHAM, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today previewed key updates that Tom Pike, chairman and chief executive...
FORTREA SELECTS COGNIZANT AS ITS TECHNOLOGY TRANSFORMATION PROVIDER
Cognizant to help Fortrea deploy a modern, secure digital ecosystem to help bring treatments to patients faster TEANECK, N.J. and DURHAM, N.C.
Fortrea to Present at the 42nd Annual J.P. Morgan Healthcare Conference
DURHAM, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Chairman and Chief Executive Officer, Tom Pike and C...
Fortrea Convenes New Site Advisory Board
Fortrea's Site Advisory Board brings research leaders together to focus on evolving site, sponsor and patient relationships Fortrea's Site Advisory Board brings research leaders together to focus on e...
Fortrea Announces AI-Driven Partnership with Medidata to Increase Diversity in Clinical Trials
Collaboration leverages Medidata AI to improve access and participation of diverse population groups in clinical studies Collaboration leverages Medidata AI to improve access and participation of dive...
Fortrea Reports Third Quarter 2023 Results
For the three months ended September 30, 2023: Revenues of $776.4 million GAAP net loss of $13.1 million Adjusted EBITDA of $70.5 million GAAP and adjusted diluted earnings (loss) per share of ($0.15)...
Starboard may be poised to build value amicably at contract research firm Fortrea
Activist Starboard Value recently disclosed a position in Fortrea Holdings. The firm may be able to take a friendly approach to building shareholder value.
This is the season for activist investors to start campaigns, says 13D's Ken Squire
Ken Squire, 13D Monitor founder and president, joins 'The Exchange' to discuss equities with shares moving higher after investor activists launched new campaigns, the strength of activist investors in...
Starboard Value Issues Presentation Delivered at 13D Monitor's 2023 Active-Passive Investor Summit
NEW YORK--(BUSINESS WIRE)--Starboard Value LP (together with its affiliates, "Starboard" or “we”) today announced that Jeffrey Smith, the firm's Chief Executive Officer and Chief Investment Officer, d...
Starboard Takes 5%-Plus Stake in Contract-Research Firm Fortrea
The activist investor plans to push for changes that could boost margins among other initiatives aimed at share-price appreciation.
Fortrea Appoints Life Science Executive Dr. John Doyle to Lead Consulting Team
Industry veteran brings more than three decades of experience spanning R&D, commercialization, and market access Industry veteran brings more than three decades of experience spanning R&D, commerciali...
Fortrea Announces Date for Third Quarter 2023 Financial Results and Conference Call
DURHAM, N.C., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its third quarter 20...
Fortrea's Jim Cameli Named a Top 100 Global Chief Information Security Officer by HotTopics
DURHAM, N.C., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that its Global Chief Information Security Officer (CISO)...
Fortrea to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
DURHAM, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Chairman and Chief Executive Officer, Tom Pike and ...
Fortrea to Present at the Baird 2023 Global Healthcare Conference
DURHAM, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Chairman and Chief Executive Officer, Tom Pike and ...
Fortrea: The Main Hurdle to Focus on Now Is Growth
Fortrea Holdings Inc. ( FTRE , Financial) is a leading provider of comprehensive phase I through IV clinical trial management, clinical pharmacology, patient access solutions and other enabling servic...
Fortrea Reports Second Quarter 2023 Results and Provides Full-Year 2023 Guidance
DURHAM, N.C., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today reported financial results for the second quarter e...